Difficulty: Intermediate | Prerequisites: Antibody structure, antigen-antibody binding, basic virology (HIV life cycle).
Monoclonal antibodies (mAbs) are lab-engineered antibodies designed to bind a single specific epitope. In HIV research, they represent both a therapeutic tool and a window into how humoral immunity works against the virus. This topic builds on your understanding of antibody function (neutralisation, opsonisation) and the HIV life cycle (receptor binding, reverse transcription, integration, replication). You need to understand how antibodies can block viral entry and why HIV is so difficult to eliminate permanently, even when viral load drops. These concepts are tested through experimental scenarios where you interpret viral load data and propose mechanisms.
Anti-HIV monoclonal antibodies can reduce viral load through two main mechanisms: neutralising the virus (blocking its entry into cells) and preventing viral DNA integration into the host genome. However, in nearly all patients, viral load rebounds after treatment, likely because the mAbs are eventually cleared from the body while latent viral reservoirs persist.
Monoclonal antibody (mAb)
An antibody produced by a single clone of B cells, meaning every molecule is identical and binds the same epitope. In simple terms, it is a highly targeted "guided missile" that recognises one specific spot on its target.
Viral load
The concentration of virus particles in a patient's blood, usually measured as copies of viral RNA per millilitre. This is the standard measure of how active an HIV infection is.
Neutralisation (in the context of antibodies)
The process by which an antibody binds to a virus and physically blocks it from attaching to or entering a host cell. Think of it as covering the virus's "key" so it cannot fit the cell's "lock."
CD4 receptor
The primary receptor on helper T cells that HIV uses to gain entry. The virus's gp120 protein binds CD4 as the first step of infection.
Integrase
A viral enzyme that inserts HIV's reverse-transcribed DNA into the host cell's genome. Once integrated, the viral DNA (provirus) can persist for the life of the cell.
Viral rebound
The return of high viral load after a period of suppression. In the mAb experiments, this occurred in nearly all patients once the antibody was cleared or overwhelmed.
ELISA (enzyme-linked immunosorbent assay)
A plate-based assay used to detect and quantify proteins such as antibodies or antigens. In this context, it can confirm whether mAbs specific to HIV are present in a blood sample.
Latent reservoir
A population of cells (mainly resting memory CD4 T cells) that harbour integrated HIV DNA but are not actively producing virus. These cells can reactivate at any time, which is a major barrier to curing HIV.
Mechanism 1: Neutralisation (blocking viral entry)
The mAb binds to HIV surface proteins (such as gp120) and physically prevents the virus from attaching to the CD4 receptor on host T cells. If the virus cannot dock with the cell, it cannot inject its RNA, and replication is blocked. Viral load falls because new infections of cells are prevented while existing infected cells die off naturally.
How to test: use ELISA to detect mAbs bound to HIV antigens in blood samples. Wells with a high degree of colour change confirm the presence of mAbs targeting HIV surface proteins. Alternatively, perform an in vitro neutralisation assay: mix HIV with the mAb and expose the mixture to susceptible cells, then measure infection compared to a no-antibody control.
Mechanism 2: Blocking viral DNA integration
The mAb may interfere with the integrase enzyme, preventing reverse-transcribed viral DNA from being inserted into the host genome. Without integration, the virus cannot establish a provirus and cannot hijack the cell's machinery for replication.
How to test: in vitro, mix a blood sample containing live HIV with the neutralising mAbs. Incubate the mixture and compare with a control sample (no mAbs). If the mAbs prevent integration, the treated sample should show significantly fewer productively infected cells (close to zero) compared to the control.
In nearly all patients, viral load rebounded after the initial drop caused by mAb infusion.
Proposed mechanism:
HIV damages secondary lymphoid tissues (lymph nodes, spleen) over time and progressively depletes CD4 T cells and other lymphocytes. Once the mAbs are cleared from the body (antibodies have a finite half-life), the virus re-emerges from latent reservoirs, resting memory CD4 T cells that harbour integrated proviral DNA. Without ongoing mAb infusion and with a weakened immune system, there is nothing to keep the virus in check, and viral load climbs again.
An alternative (and arguably stronger) explanation for rebound is simpler: the mAbs are metabolised and cleared, while the latent reservoir was never touched. The mAbs suppress free virus but do not kill cells that already contain integrated HIV DNA. Once mAb levels drop below the effective concentration, those cells reactivate and produce new virions.
How to test:
Monitor CD4 T cell and B cell counts in infected patients over time using standard blood tests. A progressive decline in lymphocyte counts alongside the viral rebound would support the immune depletion hypothesis. To test the latent reservoir hypothesis specifically, measure proviral DNA in resting CD4 T cells before and after mAb treatment; if proviral DNA levels remain unchanged, the reservoir persisted through treatment.
Students often think mAbs kill HIV-infected cells directly. Most neutralising mAbs do not. They block new infections by preventing viral entry, but they do not destroy cells that are already infected.
A common error is to assume that a drop in viral load means the virus has been eliminated. It has not. Latent reservoirs of integrated proviral DNA persist in resting memory T cells.
Students sometimes confuse neutralisation (blocking receptor binding) with opsonisation (coating a pathogen to promote phagocytosis). Both are antibody functions, but neutralisation prevents infection while opsonisation promotes clearance by phagocytes.
Another mistake is thinking that viral rebound means the mAb "stopped working." The mAb may still function perfectly; the problem is that it gets cleared from the body and the latent reservoir reactivates.
Be able to name and explain two distinct mechanisms by which mAbs reduce viral load (neutralisation and integration blocking).
Know how to design a simple experiment to test each mechanism (ELISA for detecting mAb binding; in vitro infection assay for measuring replication).
Understand why viral load rebounds and be able to propose a testable hypothesis (latent reservoir persistence, mAb clearance, immune depletion).
Recognise that this is a "propose a mechanism and test it" question format, common on exams.
True or False: Monoclonal antibodies cure HIV by eliminating all infected cells. (Answer: False. They suppress free virus but do not eliminate latently infected cells.)
Fill in the blank: Neutralising antibodies reduce viral load by blocking HIV from binding to the ______ receptor on host T cells. (Answer: CD4)
True or False: Viral rebound occurs because the mAbs mutate and lose function. (Answer: False. Rebound occurs because mAbs are cleared and latent reservoirs reactivate.)
Fill in the blank: The enzyme that inserts viral DNA into the host genome is called ______. (Answer: integrase)
True or False: ELISA can be used to detect whether mAbs specific to HIV are present in a blood sample. (Answer: True.)
Q: Name two mechanisms by which monoclonal antibodies specific to HIV could reduce viral load in infected patients. For each, describe how you would test it.
A: (1) Neutralisation: the mAb binds HIV surface proteins (e.g. gp120) and blocks the virus from attaching to the CD4 receptor, preventing entry into host cells. Test with an in vitro neutralisation assay: expose susceptible cells to HIV pre-incubated with the mAb vs. a no-antibody control, and compare infection rates. (2) Blocking integration: the mAb may interfere with integrase function, preventing viral DNA from inserting into the host genome. Test by measuring integrated proviral DNA (by PCR) in cells exposed to HIV with and without the mAb.
Q: In nearly all patients, viral load rebounded after mAb infusion. Propose a mechanism and how you would test it.
A: The mAb is metabolised and cleared from the body over time. Meanwhile, latent reservoirs of HIV (resting memory CD4 T cells with integrated proviral DNA) are not affected by the mAb, because the antibody targets free virus, not intracellular DNA. Once mAb levels drop, latently infected cells reactivate and produce new virions. Test by measuring proviral DNA in resting CD4 T cells before, during, and after mAb treatment. If proviral DNA persists unchanged throughout, the reservoir survived treatment.
Q: A patient's viral load drops by 90% within two days of mAb infusion but returns to baseline by day 14. Is the mAb defective? Explain.
A: Not necessarily. The initial 90% drop shows the mAb is effective at neutralising circulating virus. The rebound by day 14 likely reflects clearance of the mAb from the bloodstream (antibodies have a half-life of roughly 21 days for IgG) combined with reactivation of virus from latent reservoirs that the mAb cannot reach.
This topic connects to antibody structure and function (how antibodies bind antigens, the difference between neutralisation and opsonisation) and to the HIV life cycle (receptor binding via gp120/CD4, reverse transcription, integration, budding). It also links to immunodeficiency: understanding why HIV depletes CD4 T cells explains why the immune system eventually fails to control the virus even with mAb support. The concept of latent reservoirs connects to broader discussions of viral latency (e.g. herpesviruses) and why certain infections are so difficult to cure.
monoclonal antibodies, mAbs, HIV, human immunodeficiency virus, viral load, neutralisation, neutralizing antibodies, CD4 receptor, gp120, integrase, viral DNA integration, provirus, latent reservoir, viral rebound, ELISA, enzyme-linked immunosorbent assay, antibody therapy, immunotherapy, passive immunisation, HIV treatment, viral suppression, memory CD4 T cells, antibody half-life, in vitro neutralisation assay